Phospholipases: In search of a genetic base of schizophrenia

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 1-2, 1996, Pages 119-122

  Hudson, Craig J ^a   Lin, A ^a   Horrobin, David F ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b Scotia Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE; PHOSPHOLIPASE A2;

CONFERENCE PAPER; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOPHRENIA;

EID: 0029779690     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90156-8     Document Type: Conference Paper

References (31)

1. Horrobin D. F. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; 1: 936-937.
2. Horrobin D. F., Glen A. I. M., Vaddadi K. S. The membrane hypothesis of schizophrenia. Schizophr Res 1994 13: 195-207.
3. Pettegrew J., Keshavan M., Panchalingram K. et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. Arch Gen Psychiatry 1991; 48: 563-568.
4. 2 enzymes: regulation and inhibition. Trends Pharmacol Sci 1993; 14: 92-98.
5. 2 from the human monocytic cell line U937. Proc Natl Acad Sci USA 1990; 87: 7708-7712.
6. 2+-dependent translocation domain with homology to PKC and GAP. Cell 1991; 65: 1043-1051.
7. Hudson C. J., Young T., Li P. P., Warsh J. J. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993; 13: 278-293.
8. Van Kammen D., Yao J., Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann NY Acad Sci 1989; 539: 411-423.
9. Yao J. K., van Kammen D. P., Welker J. A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 1994; 13: 217-226.
10. Glen A. I. M., Glen E., Horrobin D. F. et al. A red cell membrane abnormality in a sub-group of schizophrenic patients: evidence for two diseases. Schizophr Res 1994; 12: 53-61.
11. 2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry 1987; 22: 421-426.
12. 2 acitivity in schizophrenia: a replication study. Biol Psychiatry 1990; 28: 495-501.
13. 2 activity in schizophrenia. Schizophr Res 1995; 16: 1-6.
14. Stanley J. A., Williamson P. C., Drost D. J. et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry 1995; 52: 399-406.
15. 2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989; 38: 263-274.
16. 3 and evening primrose oil. A possible objective test for monitoring therapy in schizophrenia. J Orthomolec Psychiatry 1980; 9: 33-34.
17. Hudson C. J., Lin A., Cogan S., Warsh J. J. Clinical detection of altered prostaglandin function in a schizophrenia subtype. Schizophr Res 1995; 15: 60.
18. Hudson C. J., Lin A., Cogan S., Warsh J. J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia? Biol Psychiatry submitted
19. 2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics 1995; 26: 138-141.
20. Spitzer R. L., Williams J. B. W., Gibbons M. Structured Clinical Interview for DSM-III-R (SCID). New York: New York State Psychiatric Institute, Biometric Res., 1986.
21. Chouinard G., Ross-Chouinard A., Annable L., Jones B. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7: 233.
22. Bezchilibnyk-Butler K. Z., Jeffries J. J., Martin B. A. (eds.) Clinical Handbook of Psychotropic Drugs, 4th rev ed. Toronto: Hogrefe & Huber Publishers, 1994.
23. Kay S., Opler L., Fiszbein A. Positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
24. Overall J. E., Gorham D. R. The Brief Psychiatric Rating Scale. Pscyhol Rep 1962; 10: 799-812.
25. Endicott J., Spitzer R. L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35: 837-844.
26. Niznik H. B., Van Tol H. H. M. Dopamine receptor genes: new tools for molecular psychiatry. J Psychiatr Neurosci 1992; 17: 158-180.
27. Kendler K. S., Diehl S. R. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr Bull 1993; 19: 261-285.
28. Min-induced intestinal neoplasia. Cell 1995; 81: 957-966.
29. L'hirondel M., Cheramy A., Godeheu G., Glowinski J. Effects of arachidonic acid on dopamine synthesis, spontaneous release, and uptake in striatal synaptosomes from the rat. J Neurochem 1995; 64: 1406-1409.
30. Strosznajder J., Samochocki M., Duran M. Serotonin, a potent modulator of arachidonic acid turnover, interaction with glutamatergic receptor in brain cortex. Neurochem Int 1994; 25: 193-199.
31. 2 associated with schizophrenia. Submitted for publication.